输注前多能抗CD19嵌合抗原受体T细胞与非霍奇金淋巴瘤临床结局相关
本研究对非霍奇金淋巴瘤患者输注前CD19 CAR产品进行单细胞分析,发现产品中含多能T细胞亚群,可分泌干扰素-γ、IL-17A、IL-8和巨噬细胞炎性蛋白1α等。预设的多能性强度指数(PSI)与临床反应显著相关,PSI联合CAR T细胞扩增或治疗前血清IL-15水平可提供额外显著性;多能CD4+ T细胞与临床结局的关联大于CD8+细胞。
要点
- 输注前CAR产品多能性强度指数(PSI)与临床反应显著相关。
- PSI联合CAR T细胞扩增或治疗前血清IL-15水平可提供额外显著性。
- 多能IL-17A产生T细胞与≥3级神经毒性和抗肿瘤疗效相关。
核心结论
- 输注前CAR产品中具有可定义多能表型的T细胞亚群与CAR T细胞治疗的临床结局有主要关联。
研究设计与样本
- 对非霍奇金淋巴瘤患者输注前CD19 CAR产品进行单细胞分析。
- 试验注册号NCT00924326。
主要发现
- 输注前CAR产品含多能T细胞亚群,可部署以干扰素-γ、IL-17A、IL-8和巨噬细胞炎性蛋白1α为代表的多种免疫程序。
- 预设的T细胞多能性强度指数(PSI)应用于输注前CAR产品,与临床反应显著相关。
- PSI联合CAR T细胞扩增或治疗前血清IL-15水平,提供额外显著性。
- 在总产品细胞群中,多能CD4+ T细胞与临床结局的关联大于CD8+细胞。
- ≥3级细胞因子释放综合征与多能T细胞相关;≥3级神经毒性和抗肿瘤疗效均与多能IL-17A产生T细胞相关。
局限性
- 原文称此发现来自探索性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After treatment with chimeric antigen receptor (CAR) T cells, interleukin-15 (IL-15) elevation and CAR T-cell expansion are associated with non-Hodgkin lymphoma (NHL) outcomes. However, the association of preinfusion CAR product T-cell functionality with clinical outcomes has not been reported. A single-cell analysis of the preinfusion CD19 CAR product from patients with NHL demonstrated that CAR products contain polyfunctional T-cell subsets capable of deploying multiple immune programs represented by cytokines and chemokines, including interferon-γ, IL-17A, IL-8, and macrophage inflammatory protein 1α. A prespecified T-cell polyfunctionality strength index (PSI) applied to preinfusion CAR product was significantly associated with clinical response, and PSI combined with CAR T-cell expansion or pretreatment serum IL-15 levels conferred additional significance. Within the total product cell population, associations with clinical outcomes were greater with polyfunctional CD4+ T cells compared with CD8+ cells. Grade ≥3 cytokine release syndrome was associated with polyfunctional T cells, and both grade ≥3 neurologic toxicity and antitumor efficacy were associated with polyfunctional IL-17A-producing T cells. The findings in this exploratory study show that a preinfusion CAR product T-cell subset with a definable polyfunctional profile has a major association with clinical outcomes of CAR T-cell therapy. This trial was registered at www.clinicaltrials.gov as #NCT00924326.
引用
- Rossi J, Paczkowski P, Shen YW, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018. PMID: 29895668. doi:10.1182/blood-2018-01-828343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。